Overview

Link Medicine was launched in 2005 by three men with a shared vision: Peter Lansbury, Link's founder and a leading neuroscience researcher from Harvard University, Ed Rudman, a private investor and philanthropist who less than a decade before had been diagnosed with Parkinson's disease, and Adam Rosenberg, an entrepreneur who years before saw his grandfather struggle with Parkinson's disease and his grandmother battle Alzheimer's disease.

Rather than just limited symptomatic relief for Parkinson's, Alzheimer's and other progressive neurodegenerative disorders, these men fixed their sights on tackling the root cause of the disease and forestalling, or eliminating completely, the onset of disease symptoms. As Link has grown and advanced, the urgency to help patients like Ed and Adam's grandparents remains our driving force. We are rapidly advancing our novel approaches to treating neurodegenerative diseases like Parkinson's, Alzheimer's and others through pre-clinical and early clinical testing, and anticipate that we will enter human clinical testing in a relevant disease population in 2010.

Our scientific progress, and the huge unmet need for new therapies in our targeted disease areas, has led to strong financial support, including a $40 million financing that closed in September 2008.


Overview Management Team Scientific Advisory Board Board of Directors	Overview Link Medicine was launched in 2005 by three men with a shared vision: Peter Lansbury, Link's founder and a leading neuroscience researcher from Harvard University, Ed Rudman, a private investor and philanthropist who less than a decade before had been diagnosed with Parkinson's disease, and Adam Rosenberg, an entrepreneur who years before saw his grandfather struggle with Parkinson's disease and his grandmother battle Alzheimer's disease. Rather than just limited symptomatic relief for Parkinson's, Alzheimer's and other progressive neurodegenerative disorders, these men fixed their sights on tackling the root cause of the disease and forestalling, or eliminating completely, the onset of disease symptoms. As Link has grown and advanced, the urgency to help patients like Ed and Adam's grandparents remains our driving force. We are rapidly advancing our novel approaches to treating neurodegenerative diseases like Parkinson's, Alzheimer's and others through pre-clinical and early clinical testing, and anticipate that we will enter human clinical testing in a relevant disease population in 2010. Our scientific progress, and the huge unmet need for new therapies in our targeted disease areas, has led to strong financial support, including a $40 million financing that closed in September 2008.